Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL. 3, 1999, Pages 7-10

  Dunst, Jürgen ^a,c   Weigel, Christian ^a   Heynemann, Hans ^b   Becker, Axel ^a  

^a Department of Radiotherapy ^*  (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Paclitaxel; Simultaneous radiochemotherapy; Taxol; Urinary bladder cancer

Indexed keywords

CISPLATIN; CLEMASTINE FUMARATE; DEXAMETHASONE; ERYTHROPOIETIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARESTHESIA; SKIN MANIFESTATION; TREATMENT OUTCOME;

EID: 0032867630     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03215920     Document Type: Article

References (14)

1. Becker A, Büchele T, Schöber C, et al. Zweitbestrahlung von Platte-nepithelkarzinomen im HNO-Bereich in simultaner Kombination mit Paclitaxel zweimal wöchentlich. Strahlenther Onkol 1998;174:Suppl 1:9-14.
2. Birkenhake S, Martus P, Kühn R, et al. Radiotherapy alone or radiochemotherapy with platin derivates following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. Strahlenther Onkol 1998;174:121-7.
3. Dreicer R, Gustin DM, See WA, et al. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996;156:1606-8.
4. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994;30:261-6.
5. Dunst J. Die Radiotherapie im interdisziplinären Behandlungskonzept des Harnblasenkarzinoms. Strahlenther Onkol 1991;167:563-80.
6. Gupta N, Deen DF. Comments on the use of paclitaxel as a radiation sensitizer. Int J Radiat Oncol Biol Phys 1995;33:239-40.
7. Hampel G, Rübe C, Willich N. Radiosensitizing effect of paelitaxel in vivo in a xenotransplanted human squamous cell carcinoma. J Cancer Res Clin Oncol 1995;121:728.
8. Otto T, Bex A, Krege S, et al. Paclitaxel-based second line-therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical phase II study. Cancer 1997;80:465-70.
9. Papamichael D, Gallagher CJ, Oliver RT, et al. Phase II study of paclitaxel in pretreated patients with advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606-7.
10. Roth BJ. Preliminary experience with paclitaxel in advanced bladder cancer. Semin Oncol 1995;22:Suppl 6:1-5.
11. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
12. Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexat combination chemotherapy iß active in the treatment of refractory urothelial malignancies. J Urol 1995;154:1719-22.
13. Vogt HG, Martin T, Capizello A. et al. Concurrent paclitaxel and radiotherapy. Strahlenther Onkol 1998;174:Suppl I:24-8.
14. Wenz F, Greiner S, Germa F, et al. Radiochemotherapy with paclitaxel: synchronization effects and the role of p53. Strahlenther Oncol 1999; 175:Suppl III:2-6.